Life Sciences Partners have held a final close on what is one of the largest life sciences funds in Europe. Launched in March 2014, a final close was held in June 2016 at the $280 million hard-cap, surpassing LSP V's initial $170 million target. Investments will be made primarily across Europe into medical devices and drug development.
LSP IV, the fund's predecessor, closed in April 2010 at €100 million.
Investors include Finnish Industry Investment, Bristol-Myers Squibb and the European Investment Fund.